B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care




Release Date: November 10, 2014 | Expiration Date: November 10, 2015
Media: Print with online posttest, evaluation, and request for credit

Overview

In the past several years, there has been a veritable explosion in investigational approaches and approval of novel agents for the treatment of B-cell malignancies. These developments and the rapid pace at which novel agents are entering the clinic hold the promise of revolutionizing care and improving outcomes even for high-risk patients with B-cell malignancies. This article covers the key areas in development: CD20 antibodies, BTK inhibitors, P13K inhibitors and chimeric antigen receptor-modified T cells.

If you have read article "B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care" in the November Issue of AJHO and would like to request credit, click the "Take Post-Test" button below.

Instructions For Receiving Credit

  • In order to receive a CME certificate, participants must complete the post-test and pass with a score of 70% or higher, complete the evaluation, and request for credit. Participants may immediately download a CME certificate upon completion of these steps.

If you have NOT read the article and would like to participant the online CME-certified activity, click the "Start Online Activity" button below.



Target Audience

This activity is directed toward medical oncologists and hematologists who treat patients with solid tumors and hematologic malignancies. Fellows, nurses, physician assistants, nurse practitioners, and other healthcare providers may also participate.


Learning Objectives

After participating in this CME activity, learners should be better prepared to:
  • Review current standards and emerging data regarding therapies for patients diagnosed with B-cell malignancies
  • Discuss emerging therapies for chronic lymphocytic leukemia


Medical Writer

Kathleen Krafton
Disclosure:
No relevant financial relationships with commercial interests to disclose.


The American Journal of Hematology/Oncology Editorial Board Member

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Genentech/ Roche, Pfizer, Puma, Inc. (clinical trial support contracted to University of Southern California); Consultant: Eisai, Novartis


Accreditation/ Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Acknowledgment of Commercial Support

This activity is funded by Physicians’ Education Resource®.


Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of PER® (Debbie Augustus, Ann C. Lichti, CCMEP and Megan O'Connell) as well as the Editorial Staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.

In accordance with ACCME's Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.


Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.


Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.


Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
     

Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
2627282930
Filter By

VSEO N/A